Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells

Diabetes

Volumn 55, Issue 5, 2006, Pages 1369-1379

  Koehler, Jacqueline A ^a   Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

BrdU, 5 bromo 2 deoxyuridine; CREB, cAMP responsive element binding protein; DMEM, Dulbecco's modified Eagle's medium; EGF, epidermal growth factor; EGFR, EGF receptor; ERK, extracellular regulated kinase; Ex 4, exendin 4; FBS, fetal bovine serum

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENYLATE CYCLASE; BROXURIDINE; CHOLERA TOXIN; CYCLIC AMP; CYCLOHEXIMIDE; CYCLOPAMINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EXENDIN 4; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; GLICENTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYNTOMODULIN; PEPTIDE HORMONE; PROTEIN INHIBITOR; STREPTOZOCIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; CYCLOALKANE DERIVATIVE; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; MORPHOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; DIABETES MELLITUS; DRUG INHIBITION; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GENE EXPRESSION; GENE STRUCTURE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RAT; STOMACH ACID SECRETION; STOMACH EMPTYING; CELL DIVISION; CELL SURVIVAL; DRUG EFFECT; GENETICS; KINETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHOLERA TOXIN; CHROMONES; CYCLOHEXIMIDE; CYCLOPARAFFINS; ENZYME INHIBITORS; GENES, REPORTER; HUMANS; INDOMETHACIN; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; PANCREATIC NEOPLASMS; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 33745320855     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1145     Document Type: Article

References (42)

1. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940, 2003
2. Holst JJ: Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 6:1005-1017, 1999
3. Deacon CF: Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181-2189, 2004
4. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
5. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Egan JM, Bonner-Weir S, Habener JF: Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 49:741-748, 2000
6. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158, 2003
7. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444-1455, 2003
8. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605, 2000
9. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003
10. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA: Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes 52:365-371, 2003
11. Buteau J, Foisy S, Joly E, Prentki M: Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124-132, 2003
12. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806-815, 2004
13. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366, 1999
14. Zhou J, Pineyro MA, Wang X, Doyle ME, Egan JM: Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 192:304-314, 2002
15. Hui H, Wright C, Perfetti R: Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50:785-796, 2001
16. Thorens B: Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89:8641-8645, 1992
17. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ: International Union of Pharmacology. XXXV: the glucagon receptor family. Pharmacol Rev 55:167-194, 2003
18. Drucker DJ: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171, 2003
19. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897-909, 2002
20. Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, Kelly DR, Schmid SM, Gelder FB, Rado TA, et al.: A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci U S A 87:4012-4016, 1990
21. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R: Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am J Pathol 106:250-260, 1982
22. Owens RB, Smith HS, Nelson-Rees WA, Springer EL: Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 56:843-849, 1976
23. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994
24. Yusta B, Boushey RP, Drucker DJ: The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275:35345-35352, 2000
25. Yusta B, Estall J, Drucker DJ: GLP-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896-24906, 2002
26. Trumper J, Ross D, Jahr H, Brendel MD, Goke R, Horsch D: The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells. Diabetologia 48:1534-1540, 2005
27. Park S, Dong X, Fisher TL, Dunn SL, Omer AK, Weir G, White MF: Exendin-4 uses IRS2 signaling to mediate pancreatic beta-cell growth and function. J Biol Chem 281:1159-1168, 2006
28. Goke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
29. Serre V, Dolci W, Scrocchi LA, Drucker DJ, Efrat S, Thorens B: Exendin-(9-39) as an inverse agonist of the murine GLP-1 receptor: implications for basal intracellular cAMP levels and β cell glucose competence. Endocrinology 139:4448-4454, 1998
30. MacDonald PE, Wang X, Xia F, El-kholy W, Targonsky ED, Tsushima RG, Wheeler MB: Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 278:52446-52453, 2003
31. Baggio LL, Kim JG, Drucker DJ: Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53 (Suppl. 3):S205-S214, 2004
32. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA: Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4:194-203, 1998
33. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV: Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:249-254, 2005
34. Naslund E, Backman L, Holst JJ, Theodorsson E, Hellstrom PM: Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8:253-260, 1998
35. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB: Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 4:2236-2240, 2005
36. Chepurny OG, Holz GG: Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation. Cell Tissue Res 307:191-201, 2002
37. Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW: Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 1:517-524, 2001
38. Kern SE, Hruban RH, Hidalgo M, Yeo CJ: An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 1:607-613, 2002
39. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ: Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706-2713, 2003
40. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M: A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27:210-215, 2005
41. Blase E, Taylor K, Gao HY, Wintle M, Fineman M: Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 45:570-577, 2005
42. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA: Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48:1380-1385, 2005